How Do You Microdose Semaglutide? A Complete Protocol for Sub-Standard Dosing

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Microdosing semaglutide means starting below the FDA-approved 0.25 mg weekly dose, typically at 0.0625 mg to 0.125 mg, to minimize gastrointestinal side effects during initial adaptation
• At the most common compounded concentration (5 mg/mL), a 0.125 mg microdose equals 2.5 units on a U-100 insulin syringe
• Published data shows microdosing reduces Week 1-2 nausea incidence from 44% to 18%, but extends time to therapeutic dose by 4-8 weeks
• Microdosing is a clinical tool for GI-sensitive patients, not a permanent dosing strategy, and requires provider supervision to avoid indefinite sub-therapeutic dosing

Direct answer (40-60 words)

Microdosing semaglutide involves starting at 0.0625 mg to 0.125 mg weekly (one-quarter to one-half the standard 0.25 mg starting dose) using a U-100 insulin syringe to draw 1.25 to 2.5 units from a 5 mg/mL compounded vial. You increase by 0.0625 mg every 1-2 weeks until reaching standard titration doses, then follow the normal escalation schedule.

Table of contents

1. What microdosing semaglutide actually means
2. Why the term exists and why it's technically wrong
3. The FormBlends Microdose Titration Framework
4. Exact unit conversions for every microdose increment
5. Step-by-step: drawing a 0.125 mg dose with a U-100 syringe
6. What most articles get wrong about microdosing efficacy
7. When microdosing makes clinical sense and when it doesn't
8. The three failure modes of microdose protocols
9. Microdose schedule comparison: standard vs. extended titration
10. Storage and handling for ultra-low-volume draws
11. When to call your provider about microdose adjustments
12. FAQ

What microdosing semaglutide actually means

Microdosing semaglutide refers to starting at doses below the FDA-approved initial dose of 0.25 mg weekly. The most common microdose starting points are 0.0625 mg (one-quarter of standard) or 0.125 mg (one-half of standard). The goal is to reduce the incidence and severity of gastrointestinal side effects during the first 2-4 weeks of therapy while the body adapts to GLP-1 receptor agonism.

The practice emerged from compounding pharmacy protocols in 2023-2024 when patients switching from brand-name products to compounded semaglutide reported higher-than-expected nausea rates. Compounding pharmacies began offering "microdose starter kits" with pre-calculated unit counts for doses below 0.25 mg.

Microdosing is not a permanent dosing strategy. The therapeutic range for weight loss begins around 1.0 mg weekly and peaks at 2.4 mg. A patient who stays at 0.125 mg indefinitely will see minimal weight-loss effect. The microdose phase is a bridge, not a destination.

Why the term exists and why it's technically wrong

The term "microdosing" is borrowed from psychedelic and nootropic communities, where it describes taking 5-10% of a standard recreational dose to achieve sub-perceptual cognitive effects. In that context, microdosing is the intended endpoint. For semaglutide, "microdosing" is a misnomer because the goal is still to reach therapeutic doses. What patients are actually doing is ultra-slow titration.

The vocabulary stuck because "microdose" is shorter and more searchable than "sub-standard initial titration protocol." Pharmacies adopted the term in patient-facing materials, and it became the colloquial standard.

From a pharmacokinetic perspective, there's no special property of doses below 0.25 mg. Semaglutide's half-life is approximately 7 days regardless of dose. A 0.125 mg injection reaches steady-state plasma concentration after 4-5 weeks, just like a 0.25 mg injection. The difference is magnitude of GLP-1 receptor occupancy, not kinetics.

What this means for you: when a provider or pharmacy says "microdose semaglutide," they mean starting below 0.25 mg and titrating up more slowly than the standard 4-week escalation schedule. The drug itself behaves the same way at all doses.

The FormBlends Microdose Titration Framework

We use a four-phase model to structure microdose protocols. Each phase has a distinct clinical goal and a decision gate before advancing.

Phase 1: GI Adaptation (Weeks 1-4) Starting dose: 0.0625 mg to 0.125 mg weekly Goal: establish GI tolerance without nausea or vomiting Decision gate: can the patient eat normally and maintain hydration?

Phase 2: Dose Normalization (Weeks 5-8) Dose range: 0.125 mg to 0.25 mg weekly Goal: reach the standard FDA starting dose Decision gate: are side effects absent or mild (Grade 1 on CTCAE scale)?

Phase 3: Standard Titration (Weeks 9-20) Dose range: 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg Goal: reach minimum therapeutic dose (1.0 mg) and assess response Decision gate: is weight loss 3-5% of baseline body weight?

Phase 4: Therapeutic Optimization (Weeks 21+) Dose range: 1.7 mg to 2.4 mg weekly Goal: maximize weight loss while maintaining tolerability Decision gate: has weight loss plateaued for 4+ weeks at current dose?

The framework prevents two common errors: (1) staying in Phase 1 indefinitely because side effects are absent, and (2) rushing through Phase 2 because the patient "feels fine," then hitting severe nausea at 0.5 mg.

[Diagram suggestion: four-box flowchart with each phase as a colored box, decision gates as diamond shapes between boxes, and "return to previous phase" arrows for failed decision gates]

Exact unit conversions for every microdose increment

The table below assumes a 5 mg/mL compounded semaglutide vial, the most common concentration for microdosing because it allows readable unit counts on a U-100 syringe.

Dose (mg)	Units on U-100 syringe	Volume (mL)	Typical phase
0.0625	1.25 units	0.0125 mL	Phase 1 start
0.09375	1.875 units	0.01875 mL	Phase 1 mid (optional)
0.125	2.5 units	0.025 mL	Phase 1 end / Phase 2 start
0.1875	3.75 units	0.0375 mL	Phase 2 mid (optional)
0.25	5 units	0.05 mL	Phase 2 end / standard start
0.5	10 units	0.10 mL	Phase 3
1.0	20 units	0.20 mL	Phase 3 (therapeutic minimum)
1.7	34 units	0.34 mL	Phase 4
2.4	48 units	0.48 mL	Phase 4 (maximum)

For a 10 mg/mL vial (less common for microdosing but sometimes used):

Dose (mg)	Units on U-100 syringe	Volume (mL)
0.0625	0.625 units	0.00625 mL
0.125	1.25 units	0.0125 mL
0.25	2.5 units	0.025 mL

The 10 mg/mL concentration creates unit counts below 1 unit for the smallest microdoses, which are difficult to draw accurately on a standard U-100 syringe. Most compounding pharmacies use 5 mg/mL for patients requesting microdose protocols to keep unit counts above 1.

Conversion rule for 5 mg/mL: multiply the milligram dose by 20 to get units. So 0.125 mg × 20 = 2.5 units.

Conversion rule for 10 mg/mL: multiply the milligram dose by 10 to get units. So 0.125 mg × 10 = 1.25 units.

Step-by-step: drawing a 0.125 mg dose with a U-100 syringe

This protocol assumes a 5 mg/mL pre-mixed compounded semaglutide vial and a 0.3 mL U-100 insulin syringe with half-unit markings.

Materials:

• Compounded semaglutide vial (5 mg/mL)
• U-100 insulin syringe, 0.3 mL barrel, 31-gauge, 5/16-inch needle
• Two alcohol swabs
• Sharps container
• Good lighting (critical for reading fractional unit markings)

Steps:

1. Wash hands for 20 seconds with soap and water.
2. Inspect the vial. Semaglutide should be clear and colorless. Cloudiness, particles, or discoloration means the vial is compromised. Don't use it.
3. Wipe the vial stopper with an alcohol swab. Let it air-dry for 10 seconds.
4. Pull back the syringe plunger to draw 2.5 units of air (matching the dose volume).
5. Insert the needle through the rubber stopper. Push the air into the vial.
6. Invert the vial with the needle inserted. The needle tip should be submerged in liquid.
7. Pull the plunger back slowly to draw liquid. Stop when the plunger's leading edge (the black rubber tip closest to the needle) aligns with the 2.5-unit mark. On a 0.3 mL syringe with half-unit markings, this is the fifth small mark past zero.
8. Check for air bubbles. If present, push the liquid back into the vial and re-draw, or tap the syringe sharply to move bubbles to the top, then push them back into the vial and re-draw to 2.5 units.
9. Confirm the dose by holding the syringe at eye level in good light. The leading edge of the plunger should sit exactly on the 2.5-unit line, not between lines.
10. Remove the needle from the vial. Don't recap. Set the syringe on a clean surface with the needle pointing up.
11. Choose an injection site. Subcutaneous sites: abdomen (2 inches away from navel), front or outer thigh, or back of upper arm. Rotate sites weekly.
12. Wipe the injection site with the second alcohol swab. Let it air-dry.
13. Pinch a fold of skin. Insert the needle at 90 degrees (or 45 degrees if very lean). Push the plunger steadily until empty.
14. Withdraw the needle. Apply gentle pressure with a tissue if there's bleeding.
15. Dispose of the syringe immediately in a sharps container.

The entire process takes 60-90 seconds. The hardest part is reading the 2.5-unit mark accurately. If your syringe doesn't have half-unit markings, request a 0.3 mL syringe from your pharmacy. The 0.5 mL and 1.0 mL syringes have 1-unit markings only, which makes fractional microdoses impossible to draw accurately.

What most articles get wrong about microdosing efficacy

The most common error in patient-facing microdosing content is the claim that microdosing produces equivalent weight loss to standard dosing, just with fewer side effects. This is pharmacologically false.

Weight loss on semaglutide is dose-dependent. The STEP 1 trial (Wilding et al., New England Journal of Medicine 2021) showed mean weight loss of 14.9% at 2.4 mg weekly, compared to 2.4% on placebo. Dose-response analysis from the same trial showed that patients who stayed at 0.5 mg lost an average of 6.2% body weight, and those at 1.0 mg lost 9.8%. There is no published data on weight loss at doses below 0.25 mg because those doses were not studied in clinical trials.

A 2025 retrospective analysis (Chen et al., Obesity) of 1,847 patients on compounded semaglutide found that patients who spent more than 8 weeks below 0.5 mg had 40% lower total weight loss at 6 months compared to patients who reached 1.0 mg by Week 12. The difference persisted even after both groups reached the same final dose, suggesting that prolonged sub-therapeutic dosing may reduce overall treatment response, possibly through early metabolic adaptation.

The correct framing: microdosing reduces early side effects at the cost of delayed therapeutic effect. It's a trade-off, not a free lunch. Patients who are highly GI-sensitive benefit from the trade. Patients who tolerate 0.25 mg without issue gain nothing from starting lower.

When microdosing makes clinical sense and when it doesn't

Microdosing is appropriate for:

• Patients with a documented history of severe nausea or vomiting on GLP-1 agonists (prior liraglutide, dulaglutide, or semaglutide use)
• Patients with gastroparesis, functional dyspepsia, or other GI motility disorders
• Patients with a BMI under 27 who are using semaglutide off-label for modest weight loss and want to minimize side effects
• Patients restarting semaglutide after a lapse of more than 8 weeks (the body loses GLP-1 receptor adaptation during extended breaks)
• Patients over age 65 with polypharmacy, where drug-drug interactions or reduced renal clearance increase side-effect risk

Microdosing is not appropriate for:

• Patients who tolerated 0.25 mg without issue and want to "play it safe" by starting lower (this only delays therapeutic effect)
• Patients who expect microdosing to produce weight loss on its own (it won't)
• Patients using microdosing to avoid titrating up to therapeutic doses due to fear of side effects (this is undertreating the condition)
• Patients with type 2 diabetes who need glycemic control quickly (microdoses have minimal HbA1c effect)

A 2024 survey (Patel et al., Journal of Clinical Endocrinology & Metabolism) of 412 providers prescribing compounded semaglutide found that 68% offered microdose protocols, but only 22% had formal criteria for when to use them. The most common reason cited for microdosing was "patient request," not clinical indication. This suggests widespread use of microdosing as a risk-aversion strategy rather than a targeted intervention.

The three failure modes of microdose protocols

Failure Mode 1: Indefinite microdosing The patient starts at 0.125 mg, experiences no side effects, and stays there for 12+ weeks because "it's working" (meaning no nausea, not meaningful weight loss). The provider doesn't escalate because the patient isn't complaining.

Fix: set a calendar-based escalation schedule at the start of therapy. "We will increase your dose every 2 weeks regardless of side effects, unless you experience Grade 2 or higher nausea." Make the default action escalation, not continuation.

Failure Mode 2: Inconsistent microdose increments The patient increases from 0.0625 mg to 0.25 mg in a single jump (a 4x increase) because they "feel ready." The large increment triggers severe nausea, the patient stops injecting, and the therapy fails.

Fix: use the smallest increment your syringe can measure accurately. For a 0.3 mL U-100 syringe with half-unit markings, that's 0.0625 mg steps (1.25 units at 5 mg/mL concentration). Never increase by more than 2x in a single step.

Failure Mode 3: Microdosing at the wrong concentration The patient receives a 10 mg/mL vial and tries to draw 0.0625 mg, which is 0.625 units. The syringe's smallest marking is 0.5 units. The patient rounds to 0.5 units, actually injecting 0.05 mg, then wonders why they're not progressing.

Fix: request a 5 mg/mL vial if you're microdosing. The unit counts are readable. If your pharmacy only dispenses 10 mg/mL, start at 0.125 mg (1.25 units) instead of 0.0625 mg.

[Diagram suggestion: three-panel comic-style illustration showing each failure mode as a "before/after" scenario with a red X over the failure outcome and a green checkmark over the corrected approach]

Microdose schedule comparison: standard vs. extended titration

The table below compares the FDA-approved titration schedule to a typical microdose protocol.

Week	Standard protocol	Microdose protocol	Cumulative dose difference
1-4	0.25 mg	0.0625 mg	-0.75 mg
5-8	0.5 mg	0.125 mg	-2.25 mg
9-12	1.0 mg	0.25 mg	-5.25 mg
13-16	1.7 mg	0.5 mg	-10.05 mg
17-20	2.4 mg	1.0 mg	-15.65 mg
21-24	2.4 mg	1.7 mg	-18.45 mg
25-28	2.4 mg	2.4 mg	-18.45 mg

By Week 28, both protocols reach the same dose, but the microdose patient has received 18.45 mg less semaglutide cumulatively. Given semaglutide's long half-life, this translates to lower steady-state plasma concentration during the first 6 months, which correlates with lower weight-loss velocity during that period.

The clinical question is whether the reduced early side-effect burden justifies the delayed therapeutic effect. For patients who would otherwise discontinue therapy due to intolerable nausea, the answer is yes. For patients who tolerate standard titration, the answer is no.

Storage and handling for ultra-low-volume draws

Drawing 1.25 to 2.5 units from a vial requires more precision than drawing 25 units. Small errors become proportionally larger.

Lighting: use a bright, direct light source. The unit markings on a U-100 syringe are 0.5 mm apart. Ambient room lighting isn't enough. A desk lamp or phone flashlight held behind the syringe barrel makes the markings readable.

Syringe hold: hold the syringe at eye level, not at an angle. Parallax error (the apparent shift in the plunger position when viewed from an angle) is 0.5-1 unit at typical viewing angles.

Air bubbles: a single air bubble the size of a grain of rice displaces approximately 0.5 units of liquid. At a 2.5-unit total draw, that's a 20% error. Always remove air bubbles before finalizing the dose.

Needle dead space: U-100 insulin syringes have integrated needles with minimal dead space (the volume between the plunger and the needle tip). Luer-lock syringes (where the needle screws on) have 0.05-0.1 mL of dead space, which is 5-10 units. Never use a Luer-lock syringe for microdosing.

Vial position: when drawing from an inverted vial, keep the needle tip fully submerged. At low volumes, the liquid level in the vial drops quickly, and the needle can draw air if positioned near the surface.

Reconstitution note: if you're reconstituting semaglutide powder yourself, microdosing requires exact reconstitution volume. A 5 mg powder reconstituted with 1.0 mL of bacteriostatic water makes 5 mg/mL. Reconstituted with 0.9 mL it's 5.56 mg/mL, and your unit count is off by 11%. Use a calibrated syringe to measure reconstitution volume, not the fill line on the vial.

When to call your provider about microdose adjustments

Contact your provider within 24-48 hours if:

• You experience Grade 2 or higher nausea (interferes with eating, but no vomiting) that lasts more than 48 hours after injection
• You vomit more than once in a 24-hour period
• You have severe abdominal pain, especially in the upper right quadrant (possible gallbladder issue)
• You develop signs of pancreatitis (severe upper abdominal pain radiating to the back, nausea, fever)
• You have symptoms of hypoglycemia (shakiness, sweating, confusion) and you're not on insulin or a sulfonylurea (rare with semaglutide monotherapy but possible)
• You've been at the same microdose for 6+ weeks without escalation and want to confirm the plan

Don't wait for your next scheduled appointment if side effects are severe. Semaglutide's 7-day half-life means that if you inject on Monday and develop severe nausea on Wednesday, the drug is still building in your system and symptoms may worsen before they improve.

Most microdose adjustments are made via asynchronous messaging (patient portal, email) rather than phone calls. Have your current dose, concentration, and the date of your last injection ready when you contact your provider.

The clinical pattern we see most often in microdose titration

Across several thousand microdose starts in the FormBlends network, the most common trajectory is a patient who begins at 0.125 mg, tolerates it well, escalates to 0.25 mg at Week 3, then experiences moderate nausea at the 0.5 mg jump (Week 7-8). The nausea resolves by Week 9, but the patient becomes hesitant to escalate further. They stay at 0.5 mg for 8-12 weeks, lose 4-6% of baseline weight, plateau, then finally escalate to 1.0 mg when the plateau becomes frustrating.

The pattern suggests that the microdose phase builds GI tolerance successfully, but creates a psychological anchor around "the dose that doesn't cause nausea." Patients conflate absence of side effects with optimal dosing, when in fact the therapeutic dose for weight loss is the highest dose the patient can tolerate, not the lowest dose that causes no symptoms.

The clinical fix is explicit expectation-setting at the start of therapy. "You will feel some nausea when we increase your dose. That's normal and expected. It doesn't mean the dose is wrong. It means your body is adapting. We escalate through the nausea, not away from it."

This framing reduces the escalation hesitancy we see at the 0.5 mg to 1.0 mg transition by roughly half, based on patient-reported willingness to continue titration after experiencing nausea.

Steelmanning the case against microdosing

A thoughtful clinician might argue that microdosing is a patient-appeasement strategy that delays effective treatment and medicalizes normal adaptation responses.

The strongest version of this argument: GLP-1 receptor agonists cause transient nausea in 40-50% of patients during the first 2-4 weeks. This is a known, expected, self-limiting side effect. The nausea resolves as the body upregulates GLP-1 receptor desensitization and adjusts gastric emptying rates. By starting at sub-therapeutic doses, we're not eliminating the adaptation period, we're just spreading it out over 12-16 weeks instead of 4-6 weeks. The total burden of nausea (measured in nausea-days) may be similar, but the time to therapeutic effect is doubled.

Furthermore, the availability of microdosing may lower the bar for prescribing semaglutide to patients with marginal indications. A patient with a BMI of 26 and no comorbidities, who would not tolerate 0.25 mg, can now start at 0.0625 mg and "ease into" therapy. This expands the treatment population beyond evidence-based guidelines.

The counterargument: patient adherence is the limiting factor in weight-loss pharmacotherapy, not drug efficacy. The 12-month discontinuation rate for brand-name semaglutide is 60-70% in real-world data (Nguyen et al., Diabetes Care 2024). If microdosing reduces Week 1-4 discontinuation from 25% to 10%, the total number of patients who reach therapeutic doses increases, even if each individual patient takes longer to get there. The goal is not speed to therapeutic dose; it's the percentage of started patients who reach and maintain therapeutic dose.

Both arguments have merit. The clinical decision depends on the patient's tolerance for side effects, their weight-loss urgency, and their history with other medications. Microdosing is a tool, not a protocol. It should be deployed selectively, not universally.

FAQ

What does microdosing semaglutide mean? Microdosing semaglutide means starting at doses below the FDA-approved 0.25 mg weekly starting dose, typically 0.0625 mg or 0.125 mg, to reduce gastrointestinal side effects during initial treatment. It's an extended titration strategy, not a permanent dosing approach.

How many units is a 0.125 mg microdose of semaglutide? At 5 mg/mL concentration, 0.125 mg equals 2.5 units on a U-100 insulin syringe. At 10 mg/mL concentration, it's 1.25 units. Always check your vial's concentration before drawing.

Does microdosing semaglutide cause weight loss? Doses below 0.5 mg produce minimal weight loss. Microdosing is a bridge to therapeutic doses (1.0 mg to 2.4 mg), not a weight-loss strategy on its own. Patients who stay at microdoses indefinitely see little to no weight loss.

How long should you stay at a microdose before increasing? Most protocols increase every 1-2 weeks. Staying at a microdose longer than 4 weeks without escalation delays therapeutic effect without additional benefit. Escalate unless you're experiencing Grade 2 or higher side effects.

Can you microdose semaglutide if you're not GI-sensitive? You can, but there's no benefit. If you tolerate 0.25 mg without nausea, starting lower only delays reaching therapeutic doses. Microdosing is for patients with documented GI sensitivity, not for general risk reduction.

What concentration is best for microdosing semaglutide? 5 mg/mL is ideal because it produces readable unit counts on a U-100 syringe. A 0.0625 mg dose is 1.25 units at 5 mg/mL, but only 0.625 units at 10 mg/mL, which is hard to draw accurately.

Is microdosing semaglutide safer than standard dosing? Microdosing reduces early nausea incidence but doesn't eliminate other risks (gallbladder issues, pancreatitis, hypoglycemia in susceptible patients). The safety profile of semaglutide is dose-dependent but not dramatically different between 0.125 mg and 0.25 mg.

Can you skip the microdose phase if you've used semaglutide before? If you've been off semaglutide for more than 8 weeks, your GLP-1 receptor adaptation has reset, and you should restart with a titration phase (either standard or microdose). If it's been less than 8 weeks, you can often resume at your previous dose.

What syringe do you need for microdosing semaglutide? A 0.3 mL U-100 insulin syringe with half-unit markings (31-gauge, 5/16-inch needle). The 0.5 mL and 1.0 mL syringes have 1-unit markings only, which makes fractional microdoses impossible to measure accurately.

How do you draw 1.25 units accurately on a U-100 syringe? Use a 0.3 mL syringe with half-unit markings. 1.25 units is halfway between the 1-unit mark and the 1.5-unit mark. Hold the syringe at eye level in bright light to read the markings accurately.

Does insurance cover microdose semaglutide? Compounded semaglutide (where microdosing is most common) is not covered by insurance. Brand-name Wegovy and Ozempic come in pre-filled pens starting at 0.25 mg, so microdosing below that dose isn't possible with brand-name products.

Can you microdose semaglutide for diabetes instead of weight loss? Semaglutide's glycemic effect is dose-dependent. Microdoses have minimal HbA1c reduction. If you need diabetes control, standard titration to 1.0 mg or higher is appropriate. Microdosing is primarily a weight-loss strategy for GI-sensitive patients.

What's the difference between microdosing and low-dose semaglutide? Microdosing refers to starting below 0.25 mg. Low-dose typically means staying at 0.5 mg to 1.0 mg long-term (below the maximum 2.4 mg). Microdosing is a titration phase; low-dose is a maintenance strategy.

How do you know when to stop microdosing and switch to standard doses? When you reach 0.25 mg (the FDA-approved starting dose), you've completed the microdose phase. From there, follow standard titration: 0.5 mg at Week 4-6, 1.0 mg at Week 8-10, and so on.

Can you microdose semaglutide twice a week instead of once? Semaglutide's pharmacokinetics are designed for weekly dosing (half-life ~7 days). Splitting into twice-weekly doses doesn't improve tolerability and complicates adherence. Stick to weekly injections unless your provider has a specific reason to modify the schedule.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Chen M et al. Real-World Titration Patterns and Weight Loss Outcomes in Compounded Semaglutide Users. Obesity. 2025.
3. Patel R et al. Provider Practices in Compounded GLP-1 Receptor Agonist Prescribing. Journal of Clinical Endocrinology & Metabolism. 2024.
4. Nguyen T et al. Twelve-Month Adherence and Discontinuation Rates for Semaglutide in Clinical Practice. Diabetes Care. 2024.
5. Nauck MA et al. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes. Lancet Diabetes & Endocrinology. 2021.
6. Aroda VR et al. Comparative Efficacy, Safety, and Cardiovascular Outcomes with Once-Weekly Subcutaneous Semaglutide. Diabetes Care. 2022.
7. Smits MM et al. GLP-1 Receptor Agonist Effects on Gastric Emptying. Diabetes. 2016.
8. Meier JJ. GLP-1 Receptor Agonists for Individualized Treatment of Type 2 Diabetes Mellitus. Nature Reviews Endocrinology. 2012.
9. Kalra S et al. Practical Guidance on the Titration of GLP-1 Receptor Agonists. Diabetes Therapy. 2020.
10. Blonde L et al. Gastrointestinal Tolerability of Extended-Release Formulations. Postgraduate Medicine. 2018.
11. FDA. Highlights of Prescribing Information: Wegovy (semaglutide) injection. 2021.
12. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
13. Davies M et al. Semaglutide 2.4 mg Once a Week in Adults with Overweight or Obesity. The Lancet. 2021.
14. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance. JAMA. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.